FDA says no to Bayer's request for aspirin label expansion

The U.S. regulator denies Bayer's (BAYRY +0.01%) request to change its aspirin labeling to include the claim of preventing heart attacks in patients with no history of cardiovascular disease. It cites the lack of data supporting the claim that the preventive benefits to a first attack outweigh the higher risks of bleeding in the stomach and brain.

There is evidence that the benefits of taking aspirin by patients who have already experienced a coronary event outweigh the increased risks of bleeding.

A 2010 study by Scottish researchers showed that aspirin did not prevent heart attacks or strokes in asymptomatic high risk people. The incidence of coronary events was similar to placebo.

Aspirin generated 916M euros ($1.27B) in sales last year.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs